Autolus Therapeutics Presents Positive Data on Obe-cel in B-cell ALL

Autolus Therapeutics PLC presented longer-term follow-up and additional data analysis from the pivotal phase 1b/2 Felix study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell acute lymphoblastic leukemia (ALL) at the 2024 American Society of Clinical Oncology (ASCO) annual meeting. The majority of ongoing responders showed durable responses, with 40% of patients in ongoing remission without subsequent stem cell transplant (SCT) or other therapy. At a median follow-up of 21.45 months, the overall response rate (CR/CRI) in all patients who received obe-cel in the Felix study was 78% (99/127 patients).

Furthermore, the median event-free survival (EFS) was 11.9 months, and the median overall survival (OS) was 23.8 months, with estimated 12-month EFS and OS rates of 49.5% and 61.1%, respectively. Notably, 18% of responders had SCT while in minimal residual disease (MRD)-negative remission, and 40% of responders were in ongoing remission without subsequent SCT or other therapy.

Additionally, it was observed that ongoing CAR T cell persistence was associated with improved event-free survival, while consolidative SCT for patients post-obe-cel did not appear to improve EFS or OS. Patients with loss of CAR T persistence had a 2.7 fold increased risk of relapse or death compared to patients with ongoing CAR T persistence.

The results of the Felix trial have been submitted to the FDA as part of a Biologics License Application (BLA), with the PDUFA target action date set for November 16, 2024.

Following these announcements, the company's shares moved -7.4%, and are now trading at a price of $4.17. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.